Loading

Please wait...

Ixiaro

Generic Name: Japanese encephalitis virus vaccine (SA14-14-2) (JAP a NEEZ en SEF a LYE tis VYE rus VAX een)
Brand Names: Ixiaro
Ixiaro is used for the prevention of Japanese Encephalitis. Learn about side effects, interactions and indications.
  • Prescription Settings

Prices and coupons of Ixiaro

Current Location: 20149 (Ashburn)
Change Location?

Enter your zip code


Please wait while the prices are loaded...

Don’t see your pharmacy listed? Most pharmacies accept our discounts, so have your pharmacist enter this coupon to see if you will save money:

Drug Information:
Ixiaro vaccine is used to help prevent Japanese encephalitis in adults and adolescents who are at least 17 years old. Japanese encephalitis is a serious disease caused by a virus. It is the leading cause of viral encephalitis (inflammation of the brain) in Asia. Encephalitis is an infection of the membrane around the brain and spinal cord. This infection often causes only mild symptoms, but prolonged swelling of the brain can cause permanent brain damage or death. Japanese encephalitis virus is carried and spread by mosquitoes. Learn more

Ixiaro Side Effects

Ixiaro Side Effects

Note: This document contains side effect information about japanese enceph vacc sa14-14-2, inactivated. Some of the dosage forms listed on this page may not apply to the brand name Ixiaro.

For the Consumer

Applies to japanese enceph vacc sa14-14-2, inactivated: parenteral suspension for im use

Side effects include:

Infants and children 2 months through 11 years of age: Fever, irritability, flu-like symptoms, diarrhea, vomiting, loss of appetite, rash, injection site reactions (pain, tenderness, erythema).

Adults and adolescents ≥12 years of age: Headache, myalgia, fatigue, influenza-like illness, nausea, injection site reactions (pain, tenderness, erythema, induration).

For Healthcare Professionals

Applies to japanese enceph vacc sa14-14-2, inactivated: intramuscular suspension

General

The most common adverse events in adults were injection site reactions, headache, and myalgia. The most common adverse events in adolescents (12 to under 18 years) were injection site pain and tenderness. The most common adverse event in children (1 to under 12 years) was fever. The most common adverse events in infants (2 months to under 1 year) were injection site redness, fever, irritability, and diarrhea.

Local

Very common (10% or more): Redness (17.6%), pain (15%)

Common (1% to 10%): Tenderness, swelling, hardening, induration, edema, pruritus

Gastrointestinal

Very common (10% or more): Diarrhea (11.5%)

Common (1% to 10%): Vomiting, nausea

Frequency not reported: Rectal hemorrhage

Other

Very common (10% or more): Fever over 99.9F (23.7%), flu-like symptoms (13.3%), fatigue (11.3%)

Common (1% to 10%): Excessive fatigue

Frequency not reported: Chest pain, orthopedic injuries

Musculoskeletal

Very common (10% or more): Myalgia (15.6%)

Common (1% to 10%): Back pain

Nervous system

Common (1% to 10%): Headache

Frequency not reported: Febrile convulsions, multiple sclerosis

Postmarketing reports: Paresthesia, neuritis

Febrile convulsions only occurred in patients under 3 years of age, onset was 2 days to over 5 months after vaccination with no apparent temporal clustering.

One case of multiple sclerosis was reported in adult clinical trials.

Respiratory

Common (1% to 10%): Pharyngolaryngeal pain, cough

Immunologic

Common (1% to 10%): Nasopharyngitis, rhinitis, upper respiratory tract infection

Frequency not reported: Appendicitis, limb abscess contralateral to injected arm

Dermatologic

Common (1% to 10%): Rash

Frequency not reported: Dermatomyositis

Hematologic

Disseminated intravascular coagulation after suspected bacterial meningitis leading to death occurred in a 12 year old male patient 4 months after the second dose of this vaccine.

Frequency not reported: Disseminated intravascular coagulation

Cardiovascular

Frequency not reported: Myocardial infarction

Myocardial infarction (MI) occurred in one adult patient with a history of MI, 3 weeks after receiving the second vaccine dose

Genitourinary

Frequency not reported: Ovarian torsion

Metabolic

Common (1% to 10%): Loss of appetite

Psychiatric

Very common (10% or more): Irritability (15.3%)

Editorial References and Review

Medically reviewed by BestRx Medical Team Last updated on 1/1/2020.

Source: Drugs.com Ixiaro